Filtered By:
Source: Cancer Control
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 661 results found since Jan 2013.
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
This study aimed to compare the immunogenicity of the E coli-produced HPV 9-valent vaccine Cecolin 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9.METHODS: This was a randomised, single-blind trial conducted in China. Healthy non-pregnant women aged 18-26 years, who were not breastfeeding and with no HPV vaccination history, were enrolled in the Ganyu Centre for Disease Control and Prevention (Lianyungang City, Jiangsu Province, China). Women were stratified by age (18-22 years and 23-26 years) and randomly assigned (1:1) using a permutated block size of eight to receive three doses of Cecolin 9 or Ga...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Feng-Cai Zhu Guo-Hua Zhong Wei-Jin Huang Kai Chu Li Zhang Zhao-Feng Bi Kong-Xin Zhu Qi Chen Ting-Quan Zheng Ming-Lei Zhang Sheng Liu Jin-Bo Xu Hong-Xing Pan Guang Sun Feng-Zhu Zheng Qiu-Fen Zhang Xiu-Mei Yi Si-Jie Zhuang Shou-Jie Huang Hui-Rong Pan Ying-Y Source Type: research
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis
MedComm (2020). 2023 Jul 18;4(4):e286. doi: 10.1002/mco2.286. eCollection 2023 Aug.ABSTRACTTumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines could promote a clinical benefit to advanced cancer patients is highly unknown. PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023. Random effects models were employed. Clinical benefit (objective response rate [ORR], disease control rate [DCR], 1-year/2-year progression-free survival [PFS], and overall survival [OS]) and safety (vaccine-related grade 3-5 adverse events [AEs]) were evaluated. Overall, 984 patients (32 trials) were e...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Tian-Yi Zhang Hang Xu Xiao-Nan Zheng Xing-Yu Xiong Shi-Yu Zhang Xian-Yanling Yi Jin Li Qiang Wei Jian-Zhong Ai Source Type: research
Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights
J Med Virol. 2023 Jul;95(7):e28950. doi: 10.1002/jmv.28950.ABSTRACTWith the rapid increase in the incidence of cervical cancer, anal cancer and other cancers, human papillomavirus (HPV) infection has become a growing concern. Persistent infection with high-risk HPV is a major cause of malignant tumors. In addition, microbiota and viruses such as human immunodeficiency virus, herpes simplex virus, and Epstein-Barr virus are closely associated with HPV infection. The limited effectiveness of existing treatments for HPV-associated tumors and the high rates of recurrence and metastasis in patients create an urgent need for nov...
Source: Cancer Control - July 19, 2023 Category: Cancer & Oncology Authors: Xiangjin Gong Hao Chi Zhijia Xia Guanhu Yang Gang Tian Source Type: research
COVID-19 Antibody Response in Patients with Thalassemia
Conclusion Patients with TDT manifest with mild or asymptomatic COVID-19 and mount a comparable IgG antibody response to COVID-19 akin to controls. However, this serological response could not sustain over three to six months advocating the need for protection through vaccination.PMID:37465812 | PMC:PMC10351617 | DOI:10.7759/cureus.40567
Source: Cancer Control - July 19, 2023 Category: Cancer & Oncology Authors: Nidhi Kumari Sunil Gomber Pooja Dewan Shiva Narang Rafat Ahmed Source Type: research
Measurement of Sex and Gender Identity in the Behavioral Risk Factor Surveillance System Survey, 2014 to 2020
This study examines BRFSS participant responses to gender identity and sex questions, 2014-2020. About 70% of participants who identified as transgender male-to-female reported male sex while 30% reported female sex. Participants who identified as transgender female-to-male reported female sex about 65% of the time and reported male sex 35% of the time. Despite changes in sex question wording, these percentages were consistent over time. Reported sex is used in computing health-related variables and in routing participants to questions about birth control, pregnancy, HPV vaccines, and cancer screenings. Without better meas...
Source: Cancer Control - July 19, 2023 Category: Cancer & Oncology Authors: Jenine K Harris Odalis Hernandez Source Type: research
Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
CONCLUSIONS: DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating MM-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study.PMID:37463058 | DOI:10.1158/1078-0432.CCR-23-0235
Source: Cancer Control - July 18, 2023 Category: Cancer & Oncology Authors: David J Chung Nina Shah Juan Wu Brent Logan Lina Bisharat Natalie Callander Giulia Cheloni Kenneth Anderson Thinle Chodon Binod Dhakal Steven Devine Poorvi Somaiya Dutt Yvonne Efebera Nancy Geller Haider Ghiasuddin Peiman Hematti Leona Holmberg Alan Howar Source Type: research
A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation
Hum Vaccin Immunother. 2023 Aug 1;19(2):2229222. doi: 10.1080/21645515.2023.2229222.ABSTRACTThe Japanese Ministry of Health, Labor and Welfare (MHLW) temporarily suspended recommendation for HPV vaccinations for girls in June 2013. It resumed its recommendation in November 2021. To compensate for eight years of lost overage, a 'catch-up HPV vaccination' program began in April 2022. To determine intervention needs in regards to HPV vaccine hesitancy, from October 13 2021 to April 31 2022, we surveyed 12-28 year-old vaccine-eligible males and females (281 males, 583 females). We investigated the gender and 'vaccine generatio...
Source: Cancer Control - July 18, 2023 Category: Cancer & Oncology Authors: Tatsuki Ishimoto Asami Yagi Kanon Nakajima Natsume Okamoto Erika Yukimitsu Miyo Kawasaki Yuzuki Kawae Shuma Hayasaka Yutaka Ueda Tadashi Kimura Source Type: research
Human papillomavirus vaccine acceptance among adolescent girls in Ethiopia: a systematic review and meta-analysis
CONCLUSION: Human papillomavirus vaccine acceptance of adolescent girls in Ethiopia was low. Knowledge about the vaccine and attitude to vaccination were positively associated with their vaccine acceptance. Therefore, policymakers and program planners should target school-aged adolescents in increasing their awareness and changing their attitudes to enhance their vaccine acceptance in order to prevent and control cervical cancer.PMID:37461006 | DOI:10.1186/s12889-023-16305-3
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Amare Zewdie Abebaw Wasie Kasahun Adane Habtie Anteneh Gashaw Mulat Ayele Source Type: research
Knowledge, perceptions and uptake of human papilloma virus vaccine among adolescent girls in Kampala, Uganda; a mixed-methods school-based study
CONCLUSION: Girls generally had low levels of knowledge, negative perceptions, and poor uptake of HPV vaccination. We recommend sensitization campaigns in schools and communities to improve awareness, perceptions, and practices of stakeholders towards HPV vaccination.PMID:37461002 | DOI:10.1186/s12887-023-04174-z
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Glet Kakuru Bitariho Doreen Tuhebwe Arnold Tigaiza Aisha Nalugya Tonny Ssekamatte Suzanne N Kiwanuka Source Type: research
Saturday Pap Smear Clinic: addressing barriers to cervical cancer screening
CONCLUSIONS: The availability of Saturday appointments for cervical cancer screening completion can enhance cervical cancer screening compliance among eligible women. Eliminating barriers for women can improve health outcomes.PMID:37451801 | DOI:10.1136/bmjoq-2023-002252
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Brittany Strelow Mollie Francis Gabrielle Gertner Rachel Olson Kholood Abuhadid Deqa Abdi Jordan Anderson Nicole Fellows Stephanie Fink Joy Stevens Sonya Peters Anne Stolp Johanna Tweedy Danielle O'Laughlin Source Type: research
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
ESMO Open. 2023 Jun 21;8(4):101599. doi: 10.1016/j.esmoop.2023.101599. Online ahead of print.NO ABSTRACTPMID:37450950 | DOI:10.1016/j.esmoop.2023.101599
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: S F Oosting A A M van der Veldt R S N Fehrmann A Bhattacharya R S van Binnendijk C H GeurtsvanKessel A-M C Dingemans E F Smit T J N Hiltermann G den Hartog M Jalving T T Westphal F de Wilt S M Ernst A Boerma L van Zijl G F Rimmelzwaan P Kvistborg C A C M Source Type: research
Vaccine-Boosted CAR T-cell Therapy Elicits Antigen Spreading
Cancer Discov. 2023 Jul 14:OF1. doi: 10.1158/2159-8290.CD-RW2023-112. Online ahead of print.ABSTRACTVaccine-boosted CAR T cells induce antigen spreading to control antigenically heterogeneous tumors.PMID:37449732 | DOI:10.1158/2159-8290.CD-RW2023-112
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Source Type: research
COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore: A Nationwide Cohort Study
CONCLUSION: This cohort study provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in patients with cancer. Longevity of immunity in preventing severe COVID-19 outcomes in actively treated patients with cancer, cancer survivors, and matched controls was observed at least 5 months after the third or fourth dose.PMID:37440245 | DOI:10.1001/jamaoncol.2023.2271
Source: Cancer Control - July 13, 2023 Category: Cancer & Oncology Authors: Wei Chong Tan Janice Yu Jin Tan Joline Si Jing Lim Ryan Ying Cong Tan Ainsley Ryan Yan Bin Lee Fun Loon Leong Soo Chin Lee Louis Yi Ann Chai Thuan Tong Tan Muhammad Ismail Bin Abdul Malek Benjamin Ong David Chien Lye Calvin J Chiew Wee Joo Chng Soon Thye Source Type: research
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: In this secondary cross-protocol analysis of 4 randomized clinical trials, exposure and demographic factors had the strongest associations with outcomes; results could inform mitigation strategies for SARS-CoV-2 and viruses with comparable epidemiological characteristics.PMID:37440227 | DOI:10.1001/jamanetworkopen.2023.23349
Source: Cancer Control - July 13, 2023 Category: Cancer & Oncology Authors: Deborah A Theodore Angela R Branche Lily Zhang Daniel S Graciaa Madhu Choudhary Timothy J Hatlen Raadhiya Osman Tara M Babu Samuel T Robinson Peter B Gilbert Dean Follmann Holly Janes James G Kublin Lindsey R Baden Paul Goepfert Glenda E Gray Beatriz Grin Source Type: research
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul.ABSTRACTBACKGROUND: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration.METHODS: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020. The trial's pri...
Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Melissa Bersanelli Elena Verzoni Alessio Cortellini Raffaele Giusti Lorenzo Calvetti Paola Ermacora Marilena Di Napoli Annamaria Catino Valentina Guadalupi Giorgia Guaitoli Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Fabia Source Type: research
